Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07571200
PHASE1

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group. The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.

Official title: A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-05

Completion Date

2029-06

Last Updated

2026-05-06

Healthy Volunteers

No

Interventions

DRUG

LY4256984

Administered IT

Locations (3)

UZ Leuven

Leuven, Belgium

McGill University Health Centre

Montreal, Canada

Sunnybrook Research Institute

Toronto, Canada